Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement Monrovia, CA – February 13, 2007. Xencor, Inc., a protein and antibody therapeutics development company, today announced a collaboration with Boehringer Ingelheim to optimize therapeutic monoclonal
Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures Monrovia, CA – October 19, 2006 – Xencor, a company developing protein and antibody therapeutics, today announced that it raised $45 million in a private financing led by MedImmune Ventures, Inc.,
Xencor’s XmAb™ Technology Wins Wall Street Journal 2006 Technology Innovation Award MONROVIA, CA – September 11, 2006 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, announced today that it has been named by The Wall Street Journal as a 2006 Wall Street
Xencor Completes $6 Million Bridge Financing with Novo Nordisk and Existing Investors Monrovia, CA – July 11, 2006 – Xencor, a biotherapeutics company developing protein and antibody therapeutics, today announced that it raised $6 million in a bridge financing from new investor Novo Nordisk and
Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells Monrovia, CA – March 7, 2006 – Engineering the “Fc“ region of monoclonal antibodies (mAbs) increases their toxicity to cancer cells, potentially improving the utility of targeted cancer
Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc. Monrovia, CA – February 14, 2006 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has granted Centocor Research and Development, Inc.
Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration Monrovia, CA – January 4, 2005 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced an extension to its research collaboration with Roche to create monoclonal antibodies with
MedImmune Licenses Xencor’s XmAb™ Technology To Create Antibody Therapeutics Against Select Tumor Targets; Fifth XmAb™ Deal For Xencor In The Last Year Monrovia, CA – December 7, 2005 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has
Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing MONROVIA, CA – October 18, 2005 – Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, announced today that Bassil Dahiyat, Ph.D.,